Benzimidazole-based derivatives as privileged scaffold developed for the treatment of the RSV infection: a computational study exploring the potency and cytotoxicity profiles

References

• Kong M, Maeng P, Hong J, et al. Respiratory syncytial virus infection disrupts monolayer integrity and function in cystic fibrosis airway cells. Viruses 2013;9:2260–71.
   Google Scholar
• De Clercq E. Chemotherapy of respiratory syncytial virus infections: the final breakthrough. Int J Antimicrob Agents 2015;45:234–7.
   PubMed Web of Science ®Google Scholar
• Committee on Infectious Diseases. From the American Academy of Pediatrics: policy statements-modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009;124:1694–701.
   PubMed Web of Science ®Google Scholar
• Joffe S, Ray GT, Escobar GJ, et al. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics 1999;104:419–27.
   PubMed Web of Science ®Google Scholar
• Thomas G. A cost-benefit analysis of the immunisation of children against respiratory syncytial virus (RSV) using the English Hospital Episode Statistics (HES) data set. Eur J Health Econ 2015;1–11. doi:10.1007/s10198-014-0662-9.
   PubMed Web of Science ®Google Scholar
• Collins PL, Huang YT, Wertz GW. Identification of a tenth mRNA of respiratory syncytial virus and assignment of polypeptides to the 10 viral genes. J Virol 1984;49:572–8.
   PubMed Web of Science ®Google Scholar
• DeVincenzo JP, Whitley RJ, Mackman RL, et al. Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med 2014;8:711–22.
   Web of Science ®Google Scholar
• Perron M, Stray K, Kinkade A, et al. GS-5806 inhibits a broad range of respiratory syncytial virus clinical isolates by blocking the virus-cell fusion process. Antimicrob Agents Chemother 2015;60:1264–73.
   PubMed Web of Science ®Google Scholar
• Perron M, Stray K, Kinkade A, et al. GS-5806 inhibits a broad range of respiratory syncytial virus clinical isolates by blocking the virus-cell fusion process. Antimicrob Agents Chemother 2015;pii:AAC.01497-15.
   Web of Science ®Google Scholar
• Keri RS, Hiremathad A, Budagumpi S, Nagaraja BM. Comprehensive review in current developments of benzimidazole-based medicinal chemistry. Chem Biol Drug Des 2015;86:19–65.
   PubMed Web of Science ®Google Scholar
• Boido V, Paglietti G, Tonelli M, Vitale G, Non-nucleoside benzimidazoles as antiviral drugs against HCV and RSV infections. In Carta, A., ed. RNA-viruses. Enzymatic and receptor inhibitors; Research Signpost: Kerala, 2009:40–91. ISBN: 978-81-308-0329-6.
   Google Scholar
• Cianci C, Langley DR, Dischino DD, et al. Targeting a binding pocket within the trimer-of-hairpins: small-molecule inhibition of viral fusion. Proc Natl Acad Sci USA 2004;101:15046–51.
   PubMed Web of Science ®Google Scholar
• Battles MB, Langedijk JP, Furmanova-Hollenstein P, et al. Molecular mechanism of respiratory syncytial virus fusion inhibitors. Nat Chem Biol 2016;12:87–93.
   PubMed Web of Science ®Google Scholar
• Sun Z, Pan Y, Jiang S, Lu L. Respiratory syncytial virus entry inhibitors targeting the F protein. Viruses 2013;5:211–25.
   PubMed Web of Science ®Google Scholar
• Ispas G, Koul A, Verbeeck J, et al. Antiviral activity of TMC353121, a respiratory syncytial virus (RSV) fusion inhibitor, in a non-human primate model. PLoS One 2015;10:e0126959.
   PubMed Web of Science ®Google Scholar
• Tonelli M, Novelli F, Tasso B, et al. Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents. Bioorg Med Chem 2014;22:4893–909.
   PubMed Web of Science ®Google Scholar
• Tonelli M, Simone M, Tasso B, et al. Antiviral activity of benzimidazole derivatives. II. antiviral activity of 2-phenylbenzimidazole derivatives. Bioorg Med Chem 2010;18:2937–53.
   PubMed Web of Science ®Google Scholar
• Tonelli M, Paglietti P, Boido V, et al. Antiviral activity of benzimidazole derivatives. I. Antiviral activity of 1-substituted-2-[(Benzotriazol-1/2-yl)methyl]benzimidazoles. Chem Biodivers 2008;5:2386–401.
   PubMed Web of Science ®Google Scholar
• Putz MV, Duda-Seiman C, Duda-Seiman D, et al. Chemical structure-biological activity models for pharmacophores' 3D-interactions. Int J Mol Sci 2016;17:E1087.
   Web of Science ®Google Scholar
• Duda-Seiman C, Duda-Seiman D, Dragos D, et al. Design of Anti-HIV ligands by means of minimal topological difference (MTD) method. Int J Mol Sci 2006;7:537–55.
   Web of Science ®Google Scholar
• Duda-Seiman D, Speranţa A, Mancaş S, et al. MTD-comsia modelling of HMG-CoA reductase inhibitors. J Serbian Chem Soc 2011;76:85–99.
   Web of Science ®Google Scholar
• MOE: Chemical Computing Group Inc. Montreal. H3A 2R7 Canada. Available from: www.chemcomp.com.
   Google Scholar
• Sybyl-X 1.0. Tripos Inc 1699 South Hanley Road. St Louis, Missouri 63144, USA
   Google Scholar
• Cramer RD, III, Patterson DE, Bunce JD. Comparative molecular field analysis (CoMFA). Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 1988;110:5959–67.
   PubMed Web of Science ®Google Scholar
• Klebe G, Abraham U, Mietzner T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem 1994;37:4130–46.
   PubMed Web of Science ®Google Scholar
• Cichero E, Buffa L, Fossa P. 3,4,5-Trisubstituted-1,2,4-4H-triazoles as WT and Y188L mutant HIV-1 non-nucleoside reverse transcriptase inhibitors: docking-based CoMFA and CoMSIA analyses. J Mol Model 2011;7:1537–50.
   Web of Science ®Google Scholar
• Cichero E, Cesarini S, Mosti L, Fossa P. CoMFA and CoMSIA analyses on 1,2,3,4-tetrahydropyrrolo[3,4-b]indole and benzimidazole derivatives as selective CB2 receptor agonists. J Mol Model 2010;16:1481–98.
   PubMed Web of Science ®Google Scholar
• Cichero E, Cesarini S, Fossa P, et al. Acylthiocarbamates as non-nucleoside HIV-1 reverse transcriptase inhibitors: docking studies and ligand-based CoMFA and CoMSIA analyses. J Mol Model 2009;15:871–84.
   PubMed Web of Science ®Google Scholar
• Cichero E, Fossa P. Docking-based 3D-QSAR analyses of pyrazole derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors. J Mol Model 2012;18:1573–82.
   PubMed Web of Science ®Google Scholar
• Pauwels R, Balzarini J, Baba M, et al. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods 1988;20:309–21.
   PubMed Web of Science ®Google Scholar
• Hara H, Maruyama T, Saito M, et al. Yamanouchi Pharmaceutical Co., Ltd. Patent: EP0454330A1, 1991.
   Google Scholar
• Boido V, Boido A, Canu C, Sparatore F. [Quinolozidinylalkylamines with antihypertensive activity]. Farmaco Sci 1979;34:673–87.
   PubMedGoogle Scholar
• Sparatore F, Pagani F, Some benzotryazolylalkanoic acids and their amide derivatives Farmaco Sci. 1964;19:55–75.
   Google Scholar
• Cianci C, Yu KL, Combrink K, et al. Orally active fusion inhibitor of respiratory syncytial virus. Antimicrob Agents Chemother 2004;48:413–22.
   PubMed Web of Science ®Google Scholar